Revolo Biotherapeutics
Signal active
Organization
Contact Information
Overview
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. Its mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.
Revolo Biotherapeutics was founded in 2011 and formerly known as Immune Regulation.
About
Industries
Biotechnology, Life Science, Health Care
Founded
2011
Employees
1-10
Headquarters locations
Europe
Social
N/A
Profile Resume
Revolo Biotherapeutics headquartered in Europe, operates in the Biotechnology, Life Science, Health Care sector. The company focuses on Biotechnology and has secured $1.2B in funding across 24 round(s). With a team of 1-10 employees, Revolo Biotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Revolo Biotherapeutics, raised $52.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
3
Lead Investors
0
Total Funding Amount
$52.0M
Details
2
Revolo Biotherapeutics has raised a total of $52.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | |||
| 2020 | Early Stage Venture | 52.0M |
Investors
Revolo Biotherapeutics is funded by 9 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Morningside Venture Investments | - | FUNDING ROUND - Morningside Venture Investments | 52.0M |
| Metellus | - | FUNDING ROUND - Metellus | 52.0M |
| Revolo Biotherapeutics | - | FUNDING ROUND - Revolo Biotherapeutics | 52.0M |
| 24 Haymarket | - | FUNDING ROUND - 24 Haymarket | 52.0M |
Recent Activity
There is no recent news or activity for this profile.